ARA-290: Looking Carefully at Nerve Research
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

ARA-290, also called cibinetide, was designed from a region of erythropoietin. Researchers aimed to explore tissue-protection signaling separately from stimulation of red-blood-cell production. Human studies have included people with sarcoidosis and small-fiber nerve problems. A 64-participant phase two-b trial measured corneal nerve-fiber abundance and other outcomes. Changes in nerve-fiber measurements are scientifically interesting. They still need to be separated from reliable pain relief, everyday function, and durable benefit for a wider population. A small, short study cannot settle long-term safety or show that all neuropathies respond. Cibinetide remains an experimental research story in these sources, not proof of a universal nerve-repair treatment.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Culver et al. (2017): Cibinetide and corneal nerve-fiber abundance in sarcoidosis
https://pubmed.ncbi.nlm.nih.gov/28475703/
Primary human phase 2b trial

[2] EU Clinical Trials Register: ARA-290 phase 2 results, 2013-003016-45
https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/results
Official clinical-trial registry results

EVIDENCE LIMITATIONS
Sarcoidosis-associated small-fiber neuropathy is not interchangeable with every neuropathy.
Corneal nerve-fiber area is a surrogate endpoint; avoid calling it a proven cure.
Short exposure and a small sample cannot exclude uncommon or delayed harms.
A trial registration or orphan designation does not equal marketing approval.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1564195145023928/